Table 2. Univariate analysis for the probability to achieve MR4.5.
| Features | Stratification | No. (%) | Probability to achieve MR4.5 | p |
|---|---|---|---|---|
| Age | < 50 > 50 |
30% 70% |
45% 33% |
0.03 |
| Gender | M F |
60% 40% |
31% 48% |
0.02 |
| Sokal risk | Low Interm High |
48.1% 39.9% 12% |
32% 22% 11% |
0.01 |
| EUTOS risk | Low High |
54.8% 45.2% |
47% 39% |
0.067 |
| Type of transcript | e13a2 e14a2 both |
46.6% 51.9% 1.4% |
31% 43% 42% |
0.02 |
| Median dose | 400 mg < 400 mg |
85% 15% |
43% 36% |
0.058 |
| BMI | < 30 > 30 |
80% 20% |
45% 40% |
0.12 |
| EMR at 3 months | Yes No |
70% 30% |
47% 21% |
0.001 |
| Median time of discontinuation for intolerance | < 15 days > 15 days |
75% 25% |
46% 42% |
0.24 |
| Schedule of administration | 400 mg QD 200 mg BID |
94% 6% |
45% 43% |
0.88 |
| MMR at 12 months | Yes No |
40% 60% |
69% 26% |
0.001 |